Trial · NCT02508532
Participant flow90
How many started, completed or left each group, period by period.
1 to 20 of 90
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Part 1 - Dose Determining Period | STARTED | Experimental: Part 1 Avapritinib (Formerly BLU-285) 30 mg QD | 6 | |
| Part 1 - Dose Determining Period | STARTED | Experimental: Part 1 Avapritinib (Formerly BLU-285) 60 mg QD | 6 | |
| Part 1 - Dose Determining Period | STARTED | Experimental: Part 1 Avapritinib (Formerly BLU-285) 90 mg QD | 6 | |
| Part 1 - Dose Determining Period | STARTED | Experimental: Part 1 Avapritinib (Formerly BLU-285) 135 mg QD | 6 | |
| Part 1 - Dose Determining Period | STARTED | Experimental: Part 1 Avapritinib (Formerly BLU-285) 200 mg QD | 6 | |
| Part 1 - Dose Determining Period | STARTED | Experimental: Part 1 Avapritinib (Formerly BLU-285) 300 mg QD | 6 | |
| Part 1 - Dose Determining Period | STARTED | Experimental: Part 1 Avapritinib (Formerly BLU-285) 400 mg QD | 7 | |
| Part 1 - Dose Determining Period | STARTED | Experimental: Part 1 Avapritinib (Formerly BLU-285) 600 mg QD | 3 | |
| Part 1 - Dose Determining Period | STARTED | Experimental: Part 1 and Part 2 Avapritinib (Formerly BLU-285) 300 or 400 mg QD | 0 | |
| Part 1 - Dose Determining Period | Patients From Part 1 Included in the Part 2 Analyses | Experimental: Part 1 Avapritinib (Formerly BLU-285) 30 mg QD | 0 | |
| Part 1 - Dose Determining Period | Patients From Part 1 Included in the Part 2 Analyses | Experimental: Part 1 Avapritinib (Formerly BLU-285) 60 mg QD | 0 | |
| Part 1 - Dose Determining Period | Patients From Part 1 Included in the Part 2 Analyses | Experimental: Part 1 Avapritinib (Formerly BLU-285) 90 mg QD | 0 | |
| Part 1 - Dose Determining Period | Patients From Part 1 Included in the Part 2 Analyses | Experimental: Part 1 Avapritinib (Formerly BLU-285) 135 mg QD | 0 | |
| Part 1 - Dose Determining Period | Patients From Part 1 Included in the Part 2 Analyses | Experimental: Part 1 Avapritinib (Formerly BLU-285) 200 mg QD | 0 | |
| Part 1 - Dose Determining Period | Patients From Part 1 Included in the Part 2 Analyses | Experimental: Part 1 Avapritinib (Formerly BLU-285) 300 mg QD | 6 | |
| Part 1 - Dose Determining Period | Patients From Part 1 Included in the Part 2 Analyses | Experimental: Part 1 Avapritinib (Formerly BLU-285) 400 mg QD | 7 | |
| Part 1 - Dose Determining Period | Patients From Part 1 Included in the Part 2 Analyses | Experimental: Part 1 Avapritinib (Formerly BLU-285) 600 mg QD | 0 | |
| Part 1 - Dose Determining Period | Patients From Part 1 Included in the Part 2 Analyses | Experimental: Part 1 and Part 2 Avapritinib (Formerly BLU-285) 300 or 400 mg QD | 0 | |
| Part 1 - Dose Determining Period | COMPLETED | Experimental: Part 1 Avapritinib (Formerly BLU-285) 30 mg QD | 6 | |
| Part 1 - Dose Determining Period | COMPLETED | Experimental: Part 1 Avapritinib (Formerly BLU-285) 60 mg QD | 6 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02508532/flow